ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer

Hashemi, Mehrdad; Esbati, Nastaran; Rashidi, Mohsen; Gholami, Sadaf; Raesi, Rasoul; Bidoki, Seyed Shahabadin; Goharrizi, Mohammad Ali Sheikh Beig; Motlagh, Yasamin Sadat Mousavi; Khorrami, Ramin; Tavakolpournegari, Alireza; Nabavi, Noushin; Zou, Rongjun; Mohammadnahal, Leila*; Entezari, Maliheh*; Taheriazam, Afshin*; Hushmandi, Kiavash*广东省人民医院; 广州中医药大学; 6
Translational Oncology2024-2DOI: 10.1016/j.tranon.2023.101846
13阅读
引用收藏
分享

摘要

The treatment of cancer patients has been mainly followed using chemotherapy and it is a gold standard in improving prognosis and survival rate of patients. Oxaliplatin (OXA) is a third-platinum anti-cancer agent that reduces DNA synthesis in cancer cells to interfere with their growth and cell cycle progression. In spite of promising results of using OXA in cancer chemotherapy, the process of drug resistance has made some challenges. OXA is commonly applied in treatment of colorectal cancer (CRC) as a malignancy of gastrointestinal tract and when CRC cells increase their proliferation and metastasis, they can obtain resistance to OXA chemotherapy. A number of molecular factors such as CHK2, SIRT1, c-Myc, LATS2 and FOXC1 have been considered as regulators of OXA response in CRC cells. The non-coding RNAs are able to function as master regulator of other molecular pathways in modulating OXA resistance. There is a close association between molecular mechanisms such as apoptosis, autophagy, glycolysis and EMT with OXA resistance, so that apoptosis inhibition, pro-survival autophagy induction and stimulation of EMT and glycolysis can induce OXA resistance in CRC cells. A number of anti-tumor compounds including astragaloside IV, resveratrol and nobiletin are able to enhance OXA sensitivity in CRC cells. Nanoparticles for increasing potential of OXA in CRC suppression and reversing OXA resistance have been employed in cancer chemotherapy. These subjects are covered in this review article to shed light on molecular factors resulting in OXA resistance.

学科与关键词

关键词
OxaliplatinCancer chemotherapyDrug resistanceMolecular pathwaysColorectal cancer
相关
加载中…
  • Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer
    Zhou, Yue; Zhang, Qing; Wang, Minjia; Huang, Chengzhi*; Yao, Xueqing*Frontiers in Oncology, 2022, 12: 827891.被引 5
  • Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer (vol 12, 827891, 2022)
    Zhou, Yue; Zhang, Qing; Wang, Minjia; Huang, Chengzhi*; Yao, Xueqing*Frontiers in Oncology, 2022, 12: 916983.被引 1
  • Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer
    Huang, Cheng-Zhi; Zhou, Yue; Tong, Qi-Song; Duan, Qi-Jia; Zhang, Qing; Du, Jin-Zhi*; Yao, Xue-Qing*Biomaterials, 2022, 290: 121827.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
Translational Oncology
发表日期
2024-02
卷期
第 40 卷
页码
101846
DOI
10.1016/j.tranon.2023.101846
语言
ENGLISH
成果收录
SCIE

作者

  • H

    Hashemi, Mehrdad (第一作者)

  • E

    Esbati, Nastaran

查看全部 16 位作者收起作者
  • R

    Rashidi, Mohsen

  • G

    Gholami, Sadaf

  • R

    Raesi, Rasoul

  • B

    Bidoki, Seyed Shahabadin

  • G

    Goharrizi, Mohammad Ali Sheikh Beig

  • M

    Motlagh, Yasamin Sadat Mousavi

  • K

    Khorrami, Ramin

  • T

    Tavakolpournegari, Alireza

  • N

    Nabavi, Noushin

    6

  • Z

    Zou, Rongjun

    2 · guangdong prov hosp · guangzhou univ chinese med

  • M

    Mohammadnahal, Leila (通讯)

  • E

    Entezari, Maliheh (通讯)

  • T

    Taheriazam, Afshin (通讯)

  • H

    Hushmandi, Kiavash (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417